Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2005-10-25
2008-11-18
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S236100, C424S183100, C424S194100, C424S094670, C530S350000, C530S396000, C514S002600, C514S012200, C435S252700, C435S320100, C435S069100
Reexamination Certificate
active
07452543
ABSTRACT:
A class of novel agents that are able to modify nociceptive afferent function is provided. The agents may inhibit the release of neurotransmitters from discrete populations of neurones and thereby reduce or preferably prevent the transmission of afferent pain signals from peripheral to central pain fibers. They comprise a galactose-binding lectin linked to a derivative of a clostridial neurotoxin. The derivative of the clostridial neurotoxin comprises the L-chain, or a fragment thereof, which includes the active proteolytic enzyme domain of the light (L) chain, linked to a molecule or domain with membrane translocating activity. The agents may be used in or as pharmaceuticals for the treatment of pain, particular chronic pain.
REFERENCES:
patent: 5433946 (1995-07-01), Allen, Jr. et al.
patent: 5668255 (1997-09-01), Murphy
patent: 5989545 (1999-11-01), Foster et al.
patent: 6235313 (2001-05-01), Mathiowitz et al.
patent: 6395513 (2002-05-01), Foster et al.
patent: 6461617 (2002-10-01), Shone et al.
patent: 6632440 (2003-10-01), Quinn et al.
patent: 7052702 (2006-05-01), Duggan et al.
patent: 2003/0049264 (2003-03-01), Foster et al.
patent: 2003/0147895 (2003-08-01), Shone et al.
patent: 2003/0166238 (2003-09-01), Shone et al.
patent: 2004/0071736 (2004-04-01), Quinn et al.
patent: 2005/0244435 (2005-11-01), Shone et al.
patent: 2005/0255093 (2005-11-01), Shone et al.
patent: 197 35 105 (1999-03-01), None
patent: 0 602 686 (1994-06-01), None
patent: WO 91/09871 (1991-07-01), None
patent: WO 92/15327 (1992-09-01), None
patent: WO 93/04191 (1993-03-01), None
patent: WO 93/15766 (1993-08-01), None
patent: WO 94/21300 (1994-09-01), None
patent: WO 94/28923 (1994-12-01), None
patent: WO 95/32738 (1995-12-01), None
patent: WO 96/12802 (1996-05-01), None
patent: WO 96/33273 (1996-10-01), None
patent: WO 97/18790 (1997-05-01), None
patent: WO 98/07864 (1998-02-01), None
patent: WO 98/08540 (1998-03-01), None
patent: WO 00/57897 (2000-10-01), None
Abstract of Adar, R., et al., “The amino acid sequence ofErythrina corallodendron lectinand its homology with other legume lectins,”FEBS Lett. 257:81-85, Elsevier B.V. (1989), PubMed ID 2806566.
Abstract of Arango, R., et al., “Cloning and sequence analysis of theErythrina corallodendron lectincDNA,”FEBS Lett. 264:109-111, Elsevier B.V. (1990), PubMed ID 1692539.
Abstract of Arango, R., et al., “Expression ofErythrina corallodendron lectininEscherichia coli,” Eur. J. Biochem. 205:575-581, The Federation of European Biochemical Societies and Blackwell Publishing (1992), PubMed ID 1572358.
Abstract of Arora, N., et al., “Cytotoxic effects of a chimeric protein consisting of tetanus toxin light chain and anthrax toxin lethal factor in non-neuronal cells,”J. Biol. Chem. 269:26165-26171, The American Society for Biochemistry and Molecular Biology, Inc. (1994), PubMed ID 7929330.
Abstract of Brinkmann, U., et al., “A recombinant immunotoxin containing a disulfide-stablilized Fv fragment,”Proc. Natl. Acad. Sci. USA 90:7538-7542, The National Academy of Sciences (1993), PubMed ID 8356052.
Abstract of Lamb, F.I., et al., “Nucleotide sequence of cloned cDNA coding for preproricin,”Eur. J. Biochem. 148:265-270, The Federation of European Biochemical Societies and Blackwell Publishing (1985), PubMed ID 3838723.
Abstract of Lorberboum-Galski, H., et al., “Cytotoxic activity of an interleukin 2-Pseudomonas exotoxi chimeric protein produced inEscherichia coli,” Proc. Natl. Acad. Sci. USA 85:1922-1926, The National Academy of Sciences, (1998), PubMed ID 3126499.
Abstract of Murphy, J.R., “Diphtheria-related peptide hormone gene fusions: a molecular genetic approach to chimeric toxin development,”Cancer Treat. Res. 37:123-140, Springer (1988), PubMed ID 2908622.
Abstract of O'Hare, M., et al., “Cytotoxicity of a recombinant ricin-A-chain fusion protein containing a proteolytically-cleavable spacer sequence,”FEBS Lett. 273:200-204, Elsevier B.V. (1990), PubMed ID 2121540.
Abstract of Plank, C., et al., “The influence of endosome-disruptive peptides on gene transfer using synthetic virus-like gene transfer systems,”J. Biol. Chem. 269:12918-12924, The American Society for Biochemistry and Molecular Biology, Inc. (1994), PubMed ID 8175709.
Abstract of Williams, D.P., et al., “Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein,”Protein Eng. 1:493-498, Oxford University Press (1987), PubMed ID 3334101.
Abstract of Wood, K.A., et al., “Preproabrin: genomic cloning, characterization and the expression of the A-chain inEsherichia coli,” Eur. J. Biochem. 198:723-732, The Federation of European Biochemical Societies and Blackwell Publishing (1991), PubMed ID 2050149.
Abstract of Yamaguchi, O., et al., “Chemical structures of two subunits, A-subunit and B-subunit, of galactose-specific isoelectins fromErythrina variegataseeds,”J. Biochem.(Tokyo) 114:560-566, Oxford University Press (1993), PubMed ID 8276768.
Bizzini, B., “Investigation of the Mode of Action of Tetanus Toxin With the Aid of Hybrid Molecules Consisting in Part of Tetanus Toxin-Derived Fragments,” inBacterial Protein Toxins, pp. 427-434, Academic Press London (1984).
Kurazono, H., et al., “Minimal Essential Domains Specifying Toxicity of the Light Chains of Tetanus Toxin and Botulinum Neurotoxin Type A,”J. Biol. Chem. 267:14721-14729, The American Society for Biochemistry and Molecular Biology, Inc. (1992).
Law, I.J., et al., “Cloning and expression of cDNA for galactose-binding lectin from peanut nodules,”Plant Sci. 115:71-79, Elsevier Science Ireland Ltd. (Mar. 1996).
Nathan, S. and Halina, L., “Legume lectins—a large family of homologous proteins,”FASEB J. 4:3198-3208, The Federation of American Societies for Experimental Biology (1990).
“NeuroBloc (Botulinum Toxin Type B) For Cervical Dystonia Launched in UK,” Doctor's Guide, P/S/L Consulting Group Inc. (Mar. 2001), visited online at http://www.pslgroup.com/dg/1F4216.htm on Nov. 28, 2001.
Streit, W.J., et al., “Histochemical Localization of Galactose-Containing Glycoconjugates in Sensory Neurons and Their Processes in the Central and Peripheral Nervous System of the Rat,”J. Histochem. Cytochem. 33:1042-1052, The Histochemical Society (1985).
Van Damme, E.J.M., et al., “Molecular cloning of the bark and seed lectins from the Japanese pagoda tree (Sophora japonica),”Plant Mol. Biol. 33:523-536, Kluwer Academic Publishers (Feb. 1997).
Black, J.D., and Dolly, J.O., “Interaction of125Labeled Botulinum Neurotoxins with Nerve Terminals. I. Ultrastructural Autoradiographic Localization and Quantitation of Distinct Membrane Acceptors for Types A and B on Motor Nerves,”J. Cell Biol. 103:521-534, The Rockefeller University Press (1986).
Blaustein, R.O., et al., “The N-terminal half of the heavy chain of botulinum type A neurotoxin forms channels in planar phospholipid bilayers,”FEBS Letts. 226:115-120, Elsevier Science Publishers B.V. (1987).
Shone, C.C., et al., “Inactivation ofClostridium botulinumtype A neurotoxin by trypsin and purification of two tryptic fragments. Proteolytic action near the COOH-terminus of the heavy subunit destroys toxin-binding activity,”Eur. J. Biochem. 151:75-82, Springer International (1985).
Shone, C.C., et al., “A 50-kDa fragment from the NH2-terminus of the heavy subunit ofClostridium botulinumtype A neurotoxin forms channels in lipid vesicles,”Eur. J. Biochem. 167:175-180, Springer International (1987).
Sutton, J.M., et al., “Tyrosine-1290 of tetanus neurotoxin plays a key role in its binding to gangliosides and functional binding to neurones,”FEBS Letts. 493:45-49, Elsevier Science B.V. (Mar. 2001).
Yamazaki, N., et al., “Endogenous lectins as targets for dr
Chaddock John Andrew
Duggan Michael John
Marks Philip
Kam Chih-Min
Morris Manning & Martin LLP
Raimund Christopher W.
Syntaxin Ltd.
LandOfFree
Conjugates of galactose-binding lectins and clostridial... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Conjugates of galactose-binding lectins and clostridial..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conjugates of galactose-binding lectins and clostridial... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4029422